Results 81 to 90 of about 3,281 (174)

Supplementary Material for: Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

, 2017
Romiplostim is recommended for the second- and third-line treatment of primary immune thrombocytopenia (ITP). We conducted a large, single-arm study (clinicaltrials.gov; NCT00508820) with broad entry criteria to evaluate the safety of romiplostim in ...
Boccia R.V. (4152739), Kozak T. (4152715), Dillingham K. (4152724), te Boekhorst P. (4152736), Mazzucconi M.G. (4152712), Bird R.J. (4152721), López Fernández M.F. (4152733), Tarantino M. (4152727), Steurer M. (4152730), Janssens A. (4152718)   +9 more
core   +1 more source

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

, 2018
Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Brian Elliott,2 Andrew Briggs3 1Department of Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals ...
Said Q, Tremblay G, Briggs A, Bhor M, Elliott B, Dolph M   +5 more
core  

Pharmacotherapy of chronic immune thrombocytopenic purpura (ITP) with romiplostim

, 2010
Link to a related website: http://pdfs.semanticscholar.org/5e6a/cc9b9a4ee3ced9382a33ad2df918474e94c5.pdf, Open Access via UnpaywallImmune Thrombocytopenic Purpura (ITP) has long been thought to result predominantly from immune mediated acceleration of ...
Lee, H., Perugini, M., McRae, S., D'Andrea, R.   +3 more
core   +1 more source

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use

Patient Preference and Adherence, 2020
Megan M Gilbert, Amanda B Grimes, Taylor Olmsted Kim, Jenny M Despotovic Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USACorrespondence: Megan M GilbertDepartment of Pediatrics, Section of Hematology ...
Gilbert MM, Grimes AB, Kim TO, Despotovic JM   +3 more
doaj  

Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia

, 2016
Multicenter, prospective study was conducted to evaluate the efficacy of biweekly romiplostim in maintaining platelet >/= 30 x 10(9)/L for at least 4 weeks.
Yoon, SS, Park, S, Lee, JH, Jang, JH, Lee, JW, Park, JS   +5 more
core   +1 more source

Experimental Validation a Method for Assessing Neutralizing Antibodies of Romiplostim in Human Plasma

Разработка и регистрация лекарственных средств
Introduction. Romiplostim is an analogue of the fusion protein peptide of thrombopoietin (TPO), which increases platelet count by binding and activating the human thrombopoietin receptor (TPO-R).
A. N. Afanaseva, V. B. Saparova, I. E. Makarenko, T. A. Selmenskikh, D. V. Kurkin, A. L. Hohlov, R. V. Drai   +6 more
doaj   +1 more source

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy

, 2017
David Buchbinder, Diane Nugent, Loan Hsieh Division of Hematology, CHOC Children’s Hospital and UC Irvine Medical Center, CA, USA Abstract: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia.
Nugent D, Hsieh L, Buchbinder D
core  

Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study

Background Delayed platelet recovery remains a frequent and clinically significant complication following hematopoietic stem cell transplantation (HSCT) in children, contributing to increased transfusion burden, bleeding risk, and ...
Deepam Pushpam, Aditya Kumar Gupta, Neerja Gupta, Prashant Jauhari, Biswaroop Chakrabarthy, Sameer Bakshi, Sanjana Sarangarajan, Sujata Mohanty, Jagdish Prasad Meena, Priyanka Naranje, Rachna Seth, Poonam Coshic, Sheffali Gulati   +12 more
core   +1 more source

Thrombopoietin Receptor Agonists for Chemotherapy-Induced Thrombocytopenia: A Systematic Review and Network Meta-Analysis

Journal of Clinical Question
Background: Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. However, comparative evidence for thrombopoietin receptor agonists (TPO-RAs) is limited.
Yong-Mei Guo, Yan Zhao, Toshiyoshi Maeda, Nouhaila Ezzaoui, Chinwebudu M. Melford   +4 more
doaj   +1 more source

Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune‐Mediated Thrombocytopenia

Journal of Veterinary Internal Medicine
A 2‐year‐old female spayed British Shorthair cat was diagnosed with immune‐mediated thrombocytopenia (ITP) after presenting with a 3‐week history of gastrointestinal bleeding and anemia.
Josh M. Kennils, Helen E. Wilson
doaj   +1 more source